Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.

Cho HE, Maurer BJ, Reynolds CP, Kang MH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 1;1112:16-23. doi: 10.1016/j.jchromb.2019.02.023. Epub 2019 Feb 22.

2.

Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.

Song MM, Makena MR, Hindle A, Koneru B, Nguyen TH, Verlekar DU, Cho H, Maurer BJ, Kang MH, Reynolds CP.

Anticancer Drugs. 2019 Feb;30(2):117-127. doi: 10.1097/CAD.0000000000000696.

PMID:
30272587
3.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Mohrbacher AM, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman EM, Maurer BJ.

Clin Cancer Res. 2017 Aug 15;23(16):4550-4555. doi: 10.1158/1078-0432.CCR-17-0234. Epub 2017 Apr 18.

4.

P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP.

Int J Cancer. 2017 Jul 15;141(2):405-413. doi: 10.1002/ijc.30706. Epub 2017 May 9.

5.

Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.

Chen NE, Maldonado NV, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP.

Mol Cancer Ther. 2016 Nov;15(11):2653-2664. Epub 2016 Aug 16.

6.

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.

Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ.

BMC Res Notes. 2014 Apr 23;7:256. doi: 10.1186/1756-0500-7-256.

7.

C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.

Holliday MW Jr, Cox SB, Kang MH, Maurer BJ.

PLoS One. 2013 Sep 9;8(9):e74768. doi: 10.1371/journal.pone.0074768. eCollection 2013.

8.

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A.

Pediatr Blood Cancer. 2013 Nov;60(11):1801-8. doi: 10.1002/pbc.24643. Epub 2013 Jun 29.

9.

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.

Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N.

J Mol Med (Berl). 2013 Apr;91(4):459-72. doi: 10.1007/s00109-012-0958-0. Epub 2012 Sep 30.

PMID:
23052481
10.

Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH.

Anticancer Res. 2011 Mar;31(3):961-6.

PMID:
21498721
11.

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.

Cooper JP, Hwang K, Singh H, Wang D, Reynolds CP, Curley RW Jr, Williams SC, Maurer BJ, Kang MH.

Br J Pharmacol. 2011 Jul;163(6):1263-75. doi: 10.1111/j.1476-5381.2011.01310.x.

12.

Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.

Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference.

Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414.

13.

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR.

Clin Genitourin Cancer. 2009 Jan;7(1):43-50. doi: 10.3816/CGC.2009.n.008.

PMID:
19213668
14.

N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing.

Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, Symolon H, Liu Y, Merrill AH Jr, Gouazé-Andersson V, Yu JY, Giuliano AE, Cabot MC.

Mol Cancer Ther. 2008 Sep;7(9):2967-76. doi: 10.1158/1535-7163.MCT-08-0549.

15.

N-(4-hydroxyphenyl) retinamide augments laser-induced choroidal neovascularization in mice.

Sreekumar PG, Zhou J, Sohn J, Spee C, Ryan SJ, Maurer BJ, Kannan R, Hinton DR.

Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1210-20. doi: 10.1167/iovs.07-0667.

PMID:
18326751
16.

Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells.

Kong G, Wang D, Wang H, Wu J, Bielawski J, Konopleva M, Andreeff M, Ruvolo PP, Maurer BJ.

Leukemia. 2008 Jun;22(6):1258-62. Epub 2007 Nov 22. No abstract available.

PMID:
18033322
17.

Assessing combinations of cytotoxic agents using leukemia cell lines.

Reynolds CP, Kang MH, Keshelava N, Maurer BJ.

Curr Drug Targets. 2007 Jun;8(6):765-71.

PMID:
17584032
18.

Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.

Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP.

Clin Cancer Res. 2007 May 15;13(10):3079-86.

19.

Gemella endocarditis: consider the colon.

FitzGerald SF, Moloney AC, Maurer BJ, Hall WW.

J Heart Valve Dis. 2006 Nov;15(6):833-5.

PMID:
17152793
20.

Liquid chromatography method for quantifying D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (D-threo-PPMP) in mouse plasma and liver.

Wu X, Kim Y, Sun BC, Moore JD, Shaw WA, Maurer BJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jun 6;837(1-2):44-8. Epub 2006 May 22.

PMID:
16716770
21.

Evaluating response to antineoplastic drug combinations in tissue culture models.

Reynolds CP, Maurer BJ.

Methods Mol Med. 2005;110:173-83. Review.

PMID:
15901935
23.

Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.

Vratilova J, Frgala T, Maurer BJ, Patrick Reynolds C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):125-30.

PMID:
15261805
24.

Ceramide synthesis and metabolism as a target for cancer therapy.

Reynolds CP, Maurer BJ, Kolesnick RN.

Cancer Lett. 2004 Apr 8;206(2):169-80. Review.

PMID:
15013522
25.

Retinoid therapy of high-risk neuroblastoma.

Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ.

Cancer Lett. 2003 Jul 18;197(1-2):185-92. Review.

PMID:
12880980
28.

Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.

Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ.

Med Pediatr Oncol. 2000 Dec;35(6):597-602.

PMID:
11107126
29.

Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.

Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP.

J Natl Cancer Inst. 2000 Dec 6;92(23):1897-909.

PMID:
11106681
30.

Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.

Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP.

J Natl Cancer Inst. 1999 Jul 7;91(13):1138-46.

PMID:
10393722
31.

Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers.

Maurer BJ, Ihnat MA, Morgan C, Pullman J, O'Brien C, Johnson SW, Rasey JS, Cornwell MM.

Mol Pharmacol. 1999 May;55(5):938-47.

PMID:
10220573
32.

Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy.

Fahy GJ, McCreery CJ, O'Sullivan F, Keenan AK, Quigley PJ, Maurer BJ.

Int J Cardiol. 1996 Jul 26;55(2):149-55.

PMID:
8842784
33.

Growth and radiation response of cells grown in macroporous gelatin microcarriers (CultiSpher-G).

Rasey JS, Cornwell MM, Maurer BJ, Boyles DJ, Hofstrand P, Chin L, Cerveny C.

Br J Cancer Suppl. 1996 Jul;27:S78-81.

34.

Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis.

Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ.

Chest. 1996 Jan;109(1):62-6.

PMID:
8549220
35.

Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis.

Crowley JJ, Donnelly SM, Tobin M, FitzGerald O, Bresnihan B, Maurer BJ, Quigley PJ.

Am J Cardiol. 1993 Jun 1;71(15):1337-40.

PMID:
8498377
36.

Core and peripheral temperature response to exercise in patients with impaired left ventricular function.

Griffin MJ, O'Sullivan JJ, Scott A, Maurer BJ.

Br Heart J. 1993 May;69(5):388-90.

37.

Transoesophageal echocardiography--widening the scope.

Crowley JJ, Maurer BJ.

Ir Med J. 1992 Jun;85(2):44-6. No abstract available.

PMID:
1628937
38.

Silent ischaemia in diabetic men with autonomic neuropathy.

O'Sullivan JJ, Conroy RM, MacDonald K, McKenna TJ, Maurer BJ.

Br Heart J. 1991 Oct;66(4):313-5.

39.

Cardiac catheterisation with 5 French catheters.

O'Sullivan JJ, McDonald K, Crean PA, Walsh MJ, McCarthy C, Erwin RJ, Maurer BJ.

Br Heart J. 1990 Sep;64(3):211-3.

40.

Acute and long-term hemodynamic response to low-dose enoximone in refractory heart failure.

McDonald KM, O'Sullivan JJ, McWilliams EW, Conroy RC, Maurer BJ.

Cardiovasc Drugs Ther. 1989 Dec;3(6):913-8.

PMID:
2535057
41.

Familial aortic valve disease: evidence for a genetic influence?

McDonald K, Maurer BJ.

Eur Heart J. 1989 Jul;10(7):676-7.

PMID:
2767077
42.

Novel submicroscopic extrachromosomal elements containing amplified genes in human cells.

Maurer BJ, Lai E, Hamkalo BA, Hood L, Attardi G.

Nature. 1987 Jun 4-10;327(6121):434-7.

PMID:
3587364
43.

Percutaneous transluminal coronary angioplasty in unstable angina: comparison with stable angina.

Quigley PJ, Erwin J, Maurer BJ, Walsh MJ, Gearty GF.

Br Heart J. 1986 Mar;55(3):227-30.

44.

Ventricular fibrillation during coronary angiography: association with potassium-containing glyceryl trinitrate.

Quigley PJ, Maurer BJ.

Am J Cardiol. 1985 Jul 1;56(1):191. No abstract available.

PMID:
3160229
45.

Assignment of human dihydrofolate reductase gene to band q23 of chromosome 5 and of related pseudogene psi HD1 to chromosome 3.

Maurer BJ, Carlock L, Wasmuth J, Attardi G.

Somat Cell Mol Genet. 1985 Jan;11(1):79-85.

PMID:
3856332
46.

Human dihydrofolate reductase gene is located in chromosome 5 and is unlinked to the related pseudogenes.

Maurer BJ, Barker PE, Masters JN, Ruddle FH, Attardi G.

Proc Natl Acad Sci U S A. 1984 Mar;81(5):1484-8.

47.

Mitral valve prolapse: associated skeletal and electrocardiographic abnormalities.

Gibney RT, Maurer BJ.

Ir Med J. 1980 Dec;73(12):473-6. No abstract available.

PMID:
7461937
48.

Hepatotoxicity following treatment with perhexiline maleate.

Long JP, Fitzgerald O, Maurer BJ.

Ir Med J. 1980 Jul;73(7):275-6. No abstract available.

PMID:
7440121
49.

Apparent uptake of purines by the human heart.

Nelson JA, McDaniel HG, Maurer BJ, Hill WA, James TN.

N Engl J Med. 1977 Jan 13;296(2):115. No abstract available.

PMID:
830299
50.

Hemodynamic and metabolic responses to pacing in patients with chest pain and normal coronary arteriograms.

Hill WA, Jackson DH, Maurer BJ, McDaniel HG, Soto B, Reeves TJ, James TN.

Recent Adv Stud Cardiac Struct Metab. 1975;10:159-78.

PMID:
1208972

Supplemental Content

Loading ...
Support Center